iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 **Issue:** V **Month of publication:** May 2024

DOI: https://doi.org/10.22214/ijraset.2024.59315

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 12 Issue V May 2024- Available at www.ijraset.com

Review of Oral Tablet

Amol Balasaheb Dupade[1], Pramod Shivaji Hirave[2], Vikas Bapurao Dadas[3]
Mandesh Institute of Pharmaceutical Science and Research Centre, Mhaswad

Abstract: ***Oral drug delivery is noninvasive, has a high rate of patient compliance, is easy to handle, and doesn't require any special sterile settings, it is the most popular method of administration. Nevertheless, a number of physical, biological, and pharmacological obstacles that certain medications must overcome in order to be absorbed into the systemic circulation reduce their therapeutic efficiency. The use of nanocarriers to deliver drugs orally has proven to be an effective solution to the aforementioned problems and is being explored as a potential replacement for oral medication administration. This chapter provides an overview of the latest developments in the use of nanocarriers for oral medication delivery in the treatment of different disorders. The chapter also describes how diverse nanocarrier designs and technologies improve therapeutic potential by overcoming physical, biological, and biochemical obstacles. it is easy to produce, has few sterility limitations, is less expensive, has flexible dosage form design, and has high patient compliance, oral drug delivery (ODD) is the most convenient and favored method of drug administration. However, low medication bioavailability—which is influenced by three crucial factors—is one of the difficulties associated with oral drug delivery. The other is solubility. Many mathematical models that predict the medication's rate of solubility and dissolution have been developed in order to achieve efficient drug absorption in vivo. Similarly, models that are noncellular and cellular determine permeability. Furthermore, the medication's behavior in the gastrointestinal tract (GIT) is influenced by physiological parameters, such as pH, microbial colonization, and enzymes, as well as intrinsic drug properties. A drug's dosage form is a method of getting it into a living organism. The medicine must be administered to the site of action at a rate and concentration that will maximize therapeutic benefit and minimize side effects in order to provide the intended result. Although the oral method is still commonly used, swallowing tablets and capsules can be a regular problem. As a result, numerous studies on cutting-edge drug delivery methods have been conducted. This review focuses on oral dispersible tablets, a novel approach to drug delivery systems that are currently more focused on formulation and set a new course that not only helped patients increase their level of therapy compliance.***

I. INTRODUCTION

The most popular method of administering medication is orally. Because of its benefits, which include non-invasiveness, patient compliance, and ease of medication delivery, it is the most recommended method. Drug solubility, mucosal permeability, and stability in the gastrointestinal tract environment are some of the variables that control oral drug absorption. Understanding the physicochemical, biochemical, metabolic, and biological obstacles that restrict the total drug bioavailability has been the focus of efforts to overcome these constraints. To improve oral drug absorption, a variety of pharmaceutical technologies and drug delivery methods, such as cyclodextrins, micelles, nanocarriers, and lipid-based carriers, have been investigated. In order to achieve this, the review will go over the pharmacological and physiological barriers that affect a drug's bioavailability when taken orally, along with both traditional and cutting-edge drug delivery techniques. Due to benefits like patient choice, cost-effectiveness, ease of large-scale manufacturing of oral dosage forms, and comfort of drug administration via the oral route, oral medication is the most often used method of drug administration. Approximately 60% of well- known small-molecule pharmaceutical drugs that are sold commercially are taken orally. According to current estimates, oral formulations account for approximately 90% of all pharmaceutical formulations sold worldwide that are meant for human consumption. Approximately 84% of the most popular pharmaceutical medicines are taken orally, and their current market worth is $35 billion, growing at a rate of 10% per year. Not with standing these benefits, there are still a number of difficulties in creating oral formulations, which are mostly related to the physicochemical characteristics of medications, such as their low water solubility and membrane permeability. Physiological obstacles such as pH, efflux transporters, and metabolic enzymes, combined with the poor chemical and biological stability of medications, can also limit their absorption. Additionally, some medications may result in nausea and localized discomfort (Rubbens et al., 2018). Numerous research conducted over the past 40 years have attempted to understand the mechanisms underlying medication stability in GI fluids, intestinal transit, drug absorption and transport, and the GI tract's microenvironment (Daugherty and Mrsny, 1999; Reix et al., 2012). Therefore, developing oral medication delivery devices requires a deep comprehension of the physicochemical.

II. ORAL TABLET OVERVIEW

Oral solid dose (OSD) products exist in a variety of forms, and those forms translate into a range of production methods and facility layouts. The process of producing a medication that is meant to be taken orally. Gummies, effervescence, soft gels, tablets, capsules, small molecules, and pills. All of these are what are known as oral solid dosage (OSD) forms, which are final drug product therapies that are swallowed, dissolved in the digestive system, and absorbed into the bloodstream to give the medication body.When Englishman William Brockedon developed tablets containing compressed sodium and potassium carbonate in1842, the world saw the birth of this extensively utilized and well-researched drug delivery method. This substance served as both an antacid and a calcium supplement. Oral solid dosage medication products are currently the most often prescribed dosage form by doctors for a range of conditions. There are three key reasons why oral solid dose is such a popular delivery method. It is reasonably simple to use, and it is simple to identify one oral.

III. FACTOR AFFECTING ON ORAL TABLET

solubility The primary physicochemical factors influencing the rate and degree of oral medication absorption are thought to be permeability and solubility; however, additional physicochemical characteristics constantly influence permeability and, which in turn affects drug absorption. An overview of the patient- and drug-specific factors that can influence drug absorption after oral product administration is given in this article. Any chemical substance absorbed orally represents a complicated range of processes. A product's bioavailability is influenced by permeability, in vivo dissolving rate, and medication solubility. The Biopharmaceutics Classification System has shown to be a useful tool in this regard for identifying substances that are probably linked to bioavailability issues. It also aids in determining the variables that could change the pace and degree of drug absorption. Factors related to the patient, such as the health of their gastrointestinal tract, their physiological state, the location of drug absorption, membrane transporters, presystemic drug metabolism (intrinsic variables), and external factors like

REFERENCES

[1] Lea, A.P.; McTavish, D. A Review of its Pharmacology and Therapeutic Potential in the Management of Hyperlipidaemias. Adis Drug 1997, 53, 828–847. [Google Scholar] [CrossRef] [PubMed]
[2] Athyros, V.G.; Papageorgiou, A.A.; Valasia, V.; Athyrou, V.V.; Demitriadis, D.S.; Anthimos, N.; Pehlivanidis, A.N.; Kontopoulos, A.G. Atorvastatin versus Four Statin– Fibrate Combinations in Patients with Familial Combined Hyperlipidaemia. Eur. J. Prev. Cardiol. 2002, 9, 33–39. [Google Scholar] [CrossRef]
[3] Lennernäs, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharm. 2003, 42, 1141– 1160. [Google Scholar] [CrossRef] [PubMed]
[4] Lau, Y.Y.; Okochi, H.; Huang, Y.; Benet, L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: Relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab. Dispos. 2006, 34, 1175–1181. [Google Scholar] [CrossRef] [PubMed]
[5] Paidi, S.K.; Jena, S.K.; Ahuja, B.K.; Devasari, N.; Suresh, S. Preparation, in-vitro and in- vivo evaluation of spray-dried ternary solid dispersion of biopharmaceutics classification system class II model drug. J. Pharm. Pharmacol. 2015, 67, 616–629. [Google Scholar] [CrossRef] [PubMed]
[6] Kadu, P.J.; Kushare, S.S.; Thacker, D.D.; Gattani, S.G. Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS). Pharm. Dev. Technol. 2011, 16, 65–74. [Google Scholar] [CrossRef] [PubMed]
[7] Karasulu, H.Y.; Gündoğdu, E.; Turgay, T.; Türk, U.Ö.; Apaydın, S.; Şimşir, I.Y.; Yilmaz, C.; Karasulu, E. Development and Optimization of Self-emulsifying Drug Delivery Systems (SEDDS) for Enhanced Dissolution and Permeability of Rosuvastatin. Curr. Drug. Deliv. 2016, 13, 362–370. [Google Scholar] [CrossRef] [PubMed]
[8] Shen, H.; Zhong, M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J. Pharm Pharmacol. 2006, 58, 1183–1191. [Google Scholar] [CrossRef]Govindarajan, R.; Landis, M.; Hancock, B.; Gatlin, L.A.; Suryanarayanan, R.; Shalaev,
[9] E.Y. Surface Acidity and Solid-State Compatibility of Excipients with an Acid-Sensitive API: Case Study of Atorvastatin Calcium. AAPS PharmSciTech 2015, 16, 354–363. [Google Scholar] [CrossRef]
[10] Czajkowska-Kosnik, A.; Szekalska, M.; Amelian, A.; Szymanska, E.; Winnicka, K. Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin. Molecules 2015, 20, 21010–21022. [Google Scholar] [CrossRef] [Green Version]
[11] Gumaste, S.G.; Pawlak, S.A.; Dalrymple, D.M.; Nider, C.J.; Trombetta, L.D.; Serajuddin, A.T.M. Development of Solid SEDDS, IV: Effect of Adsorbed Lipid and Surfactant on Tableting Properties and Surface Structures of Different Silicates. Pharm. Res. 2013, 30, 3170–3185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
[12] Nikolakakis, I.; Partheniadis, I. Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release. Pharmaceutics 2017, 9, 50. [Google Scholar] [CrossRef] [PubMed]
[13] Tuleu, C.; Newton, M.; Rose J Euler, D.; Saklatvala, R.; Clarke, A.; Booth, S. Comparative Bioavailability Study in Dogs of a Self-Emulsifying Formulation of Progesterone Presented in a Pellet and Liquid Form Compared with an Aqueous Suspension of Progesterone. J. Pharm. Sci. 2004, 93, 1495–1502. [Google Scholar] [CrossRef] [PubMed]
[14] Jukkola, A.; Partanen, R.; Xiang, W.; Heino, A.; Rojas, O.J. Food emulsifiers based on milk fat globule membranes and their interactions with calcium and casei phosphoproteins. Food Hydrocoll 2019, 94, 30–37. [Google Scholar] [CrossRef] [Green Version
[15] Yildirim, S.T.; Oztop, M.H.; Soyer, Y. Cinnamon oil nanoemulsions by spontaneous emulsification: Formulation, characterization and antimicrobial activity. LWT Food Sci. Technol. 2017, 84, 122–128. [Google Scholar] [CrossRef]

[16] Wagner, K.G.; Krumme, M.; Schmidt, P.C. Investigation of the pellet-distribution in single tablets via image analysis. Eur. J. Pharm. Biopharm. 1999, 47, 79–85. [Google Scholar] [CrossRef]
[17] Matsaridou, I.; Barmpalexis, P.; Salis, A.; Nikolakakis, I. The influence of surfactant HLB and oil/surfactant ratio on the formation and properties of Self-emulsifying pellets and microemulsion reconstitution. AAPS PharmSciTech 2012, 13, 1319–1330. [Google Scholar] [CrossRef]
[18] Gopal, E.S.R. Emulsion Science; Sherman, P., Ed.; Academic Press: New York, NY, USA, 1968; pp. 43–54. [Google Scholar]
[19] Zetasizer Nanoseries User Mannual MANO 317 Issue 2.2; Malvern Instruments Ltd.: Worcestershire, UK, 2005; p. 16.2.
[20] Almeida-Prieto, S.; Blanco-Méndez, J.; Francisco JOtero-Espinar, F.J. Image Analysis of the Shape of Granulated Powder Grains. J. Pharm. Sci. 2004, 93, 621–634. [Google Scholar] [CrossRef]
[21] Fell, J.T.; Newton, J.M. Determination of Tablet Strength by the Diametral-Compression Test. J. Pharm. Sci. 1970, 59, 688–691. [Google Scholar] [CrossRef]
[22] Choudhary, A.; Rana, A.C.; Aggarwal, G.; Kumar, V.; Zakir, F. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharm. Sin. B 2012, 2, 421–428. [Google Scholar] [CrossRef] [Green Version]
[23] Başpınar, Y.; Gündoğdu, E.; Köksal, C. Pitavastatin-containing nanoemulsions: Preparation, characterization and in vitro cytotoxicity. J. Drug Deliv. Sci. Technol. 2015, 29, 117–124. [Google Scholar] [CrossRef]
[24] Bandivadekar, M.; Pancholi, S.; Kaul-Ghanekar, R.; Choudhari, A.; Koppikar, S. Single non-ionic surfactant based selfnanoemulsifying drug delivery systems: Formulation, characterization, cytotoxicity and permeability enhancement study. Drug Dev. Ind. Pharm. 2013, 39, 696–703. [Google Scholar] [CrossRef] [PubMed]
[25] Dalvadi, H.; Patel, N.; Parmar, K. Systematic development of design of experiments (DoE) optimised self-microemulsifying drug delivery system of Zotepine. J. Microencapsul. 2017, 34, 308–318. [Google Scholar] [CrossRef] [PubMed]
[26] Quan, D.; Xu, G.; Wu, X. Studies on Preparation and Absolute Bioavailability of a Self- Emulsifying System Containing Puerarin. Chem. Pharm. Bull. 2007, 55, 800–803. [Google Scholar] [CrossRef] [Green Version]
[27] Zhu, J.; Tang, D.; Feng, L.; Zheng, Z.; Wang, R.; Wu, A.; Duan, T.; He, B.; Zhu, Q. Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride. Drug Dev. Ind. Pharm. 2013, 39, 499–506. [Google Scholar] [CrossRef]
[28] Pouton, W.C. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 2006, 29, 278–287. [Google Scholar] [CrossRef] [PubMed]
[29] Magdassi, S.M.; Frenkel, M.; Garti, N. Correlation Between Nature of Emulsifier and Multiple Emulsion Stability. Drug Dev. Ind. Pharm. 1985, 11, 791–798. [Google Scholar] [CrossRef]
[30] Agrawal, A.G.; Kumar, A.; Gide, P.S. Formulation of solid self-nanoemulsifying drug delivery systems using N-methyl pyrrolidone as cosolvent. Drug Dev. Ind. Pharmac. 2015, 41, 594–604. [Google Scholar] [CrossRef]



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY